Johan Vingerhoets

机构：Johnson & Johnson (United States) · ORCID：0000-0001-5939-9501

发表论文 110 篇 · 总被引 5084 次 · h-index 34

代表论文

• Final Analysis of Efficacy and Safety of Single-Dose Ad26.COV2.S (2022 · New England Journal of Medicine · 被引 254)
• Genotypic and Phenotypic Characterization of HIV-1 Isolates Obtained From Patients on Rilpivirine Therapy Experiencing Virologic Failure in the Phase 3 ECHO and THRIVE Studies (2011 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 175)
• Phase 2b Study of Pimodivir (JNJ-63623872) as Monotherapy or in Combination With Oseltamivir for Treatment of Acute Uncomplicated Seasonal Influenza A: TOPAZ Trial (2018 · The Journal of Infectious Diseases · 被引 140)
• Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials (2010 · Antiviral Therapy · 被引 102)
• Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial (2022 · The Lancet Infectious Diseases · 被引 90)
• Effect of Mutations at Position E138 in HIV-1 Reverse Transcriptase on Phenotypic Susceptibility and Virologic Response to Etravirine (2011 · JAIDS Journal of Acquired Immune Deficiency Syndromes · 被引 78)